HEMRYZIQ Trademark

Trademark Overview

On Wednesday, January 10, 2024, a trademark application was filed for HEMRYZIQ with the United States Patent and Trademark Office. The USPTO has given the HEMRYZIQ trademark a serial number of 98351118. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, October 22, 2024. This trademark is owned by Pfizer Inc.. The HEMRYZIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; Pharmaceutical preparations for the treatment of sickle cell disease; pharmaceutical preparations for the treatment of hypoxic and hypoxemic conditions
hemryziq

General Information

Serial Number98351118
Word MarkHEMRYZIQ
Filing DateWednesday, January 10, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, October 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 27, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; Pharmaceutical preparations for the treatment of sickle cell disease; pharmaceutical preparations for the treatment of hypoxic and hypoxemic conditions

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 10, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192

Trademark Events

Event DateEvent Description
Wednesday, January 10, 2024NEW APPLICATION ENTERED
Tuesday, April 30, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 18, 2024ASSIGNED TO EXAMINER
Wednesday, July 24, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 7, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 27, 2024PUBLISHED FOR OPPOSITION
Tuesday, August 27, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 22, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Related Keywords

hemryziq preparations pharmaceutical disorders treatment obesity diabetes namely stroke anti pain